NEWS

October 2010 The Indian Journal of Medical Research recently published an article reporting the prevalence of the JAK2 mutation among polycythemia vera, essential thrombocythemia and myelofibrosis patients at a clinic in northern India. The JAK2 mutation, a gene marker for the Myeloproliferative disorders, was discovered in 2005. To read the full article click here.

The September 2010 issue of Blood included an article on a new model for estimating risk of blood clot for a variety of cancer patients. Patients with the hematological malignancies lymphoma and multiple myeloma were included in the study along with hard tumor patients to develop a model by which doctors could better predict risk.… Read More »ASH PRESS RELEASE ON BLOOD CLOT RISK PREDICTION MODEL

September 2010 The FDA has approved a special protocol for Incyte’s clinical trial for Polycythemia Vera patients. Their RESPONSE (Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care) is expected to enroll approximately… Read More »INCYTE APPROVED BY FDA FOR SPECIAL PV PROTOCOL

TargeGen, producer of JAK2 inhibitor TG101348, was purchased on June 30 2010 by French pharmaceutical company Sanofi-Aventis. Sanofi-Aventis hopes to continue to develop drugs targeted at hematological malignancies. Clinical trials for TG101348 have completed enrollment. For the full press release click here.

The MPD Foundation is pleased to announce a Call for Proposals for its 2011 Challenge Grant Program. Worthy projects will advance the understanding of mechanisms of action in the MPD’s and/or contribute to accelerating the discovery and development of new treatments for MPD patients. The MPD Foundation is a private not-for-profit advocacy organization seeking to… Read More »ANNOUNCING CHALLENGE GRANT 2011

03/18/2008 Cytopia Limited (ASX:CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease. Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential… Read More »CYTOPIA NOMINATES JAK2 CLINICAL CANDIDATE FOR MYELOPROLIFERATIVE DISORDERS

Wilmington, Del. — (Business Wire) — Incyte Corporation (Nasdaq: INCY) today reported full year and fourth quarter 2007 financial results, and announced its 2008 financial guidance and key objectives and plans for its rapidly expanding clinical pipeline. Paul A. Friedman, M.D., President and CEO of Incyte, state, “Over the past year, we’ve worked intensively to… Read More »INCYTE REPORTS PROGRESS IN MULTIPLE CLINICAL PROGRAMS AND EXPANDS JAK INHIBITOR PROGRAM

San Diego, CA – January 31, 2008 – TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases. The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia… Read More »TARGEGEN ANNOUNCES INITIATION OF CLINICAL TRIAL OF JAK2 INHIBITOR TG101348 IN MYELOPROLIFERATIVE DISEASE PATIENTS

MELBOURNE, Australia, Jan. 30 /PRNewswire/ — Australian and New York based company Cytopia Limited announced today that its lead JAK2 inhibitor compound CYT387 has demonstrated potent activity in cells isolated from patients with myeloproliferative disorders (MPDs). MPDs are a series of diseases where there is over-production of particular cells within the blood stream. One of… Read More »JAK2 INHIBITOR SHOWS POTENT ACTIVITY IN CELLS FROM MPD PATIENTS

12/10/2007 2:06:40 PM Monday afternoon, Exelixis, Inc. (EXEL), a developer of therapies for the treatment of cancer and other serious diseases, announced data from an ongoing Phase 1 trial of XL019 to treat patients with myelofibrosis, a myeloproliferative disorder, or MPD. The primary objective of the trial is to determine the safety and tolerability of… Read More »EXELIXIS REPORTS DATA FROM ONGOING PHASE 1 STUDY OF XL019 TO TREAT MYELOFIBROSIS – UPDATE